Azura Ophthalmics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $22M

  • Investors
  • 6

Azura Ophthalmics General Information

Description

Developer of ophthalmic keratolytic intended for the treatment of disorders affecting the lid margin and ocular surface. The company is developing an innovative portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for Meibomian Gland Dysfunction (MGD), enabling healthcare professionals to approach the treatment of ocular surface disease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5 Druyanov Street
  • Tel Aviv 6314305
  • Israel
+972
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 5 Druyanov Street
  • Tel Aviv 6314305
  • Israel
+972

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Azura Ophthalmics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 11-Feb-2022 $22M Completed Clinical Trials - Phase 3
4. Later Stage VC (Series C) 22-Oct-2020 Completed Clinical Trials - Phase 3
3. Later Stage VC (Series C) 19-Jan-2020 Cancelled Clinical Trials - Phase 2
2. Early Stage VC (Series B) 10-Oct-2017 $16M $17.2M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 11-Mar-2014 $1.2M $1.2M Completed Startup
To view Azura Ophthalmics’s complete valuation and funding history, request access »

Azura Ophthalmics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preferred B
Preferred A
To view Azura Ophthalmics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Azura Ophthalmics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of ophthalmic keratolytic intended for the treatment of disorders affecting the lid margin and ocular surface.
Drug Discovery
Tel Aviv, Israel
11 As of 2023

Heidelberg, Germany
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Azura Ophthalmics Competitors (1)

One of Azura Ophthalmics’s competitors is Novaliq, a Venture Capital-Backed company based in Heidelberg, Germany.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novaliq Venture Capital-Backed Heidelberg, Germany
You’re viewing 1 of 1 competitors. Get the full list »

Azura Ophthalmics Patents

Azura Ophthalmics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260174877-A1 Compounds and methods for the treatment of dermal and ocular disorders Pending 19-Dec-2024
US-20260053711-A1 Semi-solid pharmaceutical composition micro-dispenser Pending 20-Aug-2024
WO-2026041906-A1 Semi-solid pharmaceutical composition micro-dispenser Pending 20-Aug-2024
EP-4739291-A2 Administration of keratolytics to ocular and periocular surfaces Pending 07-Jul-2023
WO-2025012701-A2 Administration of keratolytics to ocular and periocular surfaces Inactive 07-Jul-2023 A61K9/0048
To view Azura Ophthalmics’s complete patent history, request access »

Azura Ophthalmics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Azura Ophthalmics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Brandon Biocatalyst Venture Capital Minority
Brandon Capital Venture Capital Minority
OrbiMed Growth/Expansion Minority
TPG PE/Buyout Minority
Elron Ventures Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Azura Ophthalmics FAQs

  • When was Azura Ophthalmics founded?

    Azura Ophthalmics was founded in 2013.

  • Where is Azura Ophthalmics headquartered?

    Azura Ophthalmics is headquartered in Tel Aviv, Israel.

  • What is the size of Azura Ophthalmics?

    Azura Ophthalmics has 11 total employees.

  • What industry is Azura Ophthalmics in?

    Azura Ophthalmics’s primary industry is Drug Discovery.

  • Is Azura Ophthalmics a private or public company?

    Azura Ophthalmics is a Private company.

  • What is Azura Ophthalmics’s current revenue?

    The current revenue for Azura Ophthalmics is .

  • How much funding has Azura Ophthalmics raised over time?

    Azura Ophthalmics has raised $59.2M.

  • Who are Azura Ophthalmics’s investors?

    Brandon Biocatalyst, Brandon Capital, OrbiMed, TPG, and Elron Ventures are 5 of 6 investors who have invested in Azura Ophthalmics.

  • Who are Azura Ophthalmics’s competitors?

    Novaliq is a competitor of Azura Ophthalmics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process